{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T15:37:56Z","timestamp":1794584276093,"version":"4.9.1"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T00:00:00Z","timestamp":1756339200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T00:00:00Z","timestamp":1756339200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","award":["5M-2020-23683645"],"award-info":[{"award-number":["5M-2020-23683645"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Exp Clin Cancer Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Diffuse Pleural Mesothelioma (DPM) is a rare and incurable cancer. Immune checkpoint inhibitors (ICIs) marked some advances but only for a limited fraction of patients. Improving response prediction to ICIs is currently a clinical need in DPM. Deletion of CDKN2A gene, in chr9p21.3, is one of the most frequent alterations in DPM. As in other settings, deletion of CDKN2A locus has been associated with an immunosuppressive phenotype. Here we investigated the consequences of CDKN2A deletion (CDKN2Adel) on the tridimensional organization and function of immune infiltrate in DPM.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A retrospective cohort of 89 DPMs was analyzed and assessed for CDKN2Adel through digital droplet PCR. Immune-profiling was assessed by analyzing 770 immune-related genes by digital profiling. Finally, morphologically resolved, high-dimensional transcriptomic approach was used to reconstruct the spatial architecture of immune-tumor interaction in wild-type and deleted FFPE samples.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      CDKN2Adel was detected in 41.5% of DPMs and was associated with reduced survival (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.04). Bulk gene expression identified 373 differentially expressed genes, of which 98.6% were downregulated in CDKN2Adel samples. These genes were enriched in several immune categories, suggesting significant immune deprivation in deleted tumors. Deconvolution analysis confirmed a major depletion of infiltrating immune cells including effector populations. Spatial transcriptomics revealed that this immunosuppressive phenotype was different according to histotype and prominent in the sarcomatoid lesions.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>These data demonstrated that CDKN2Adel deeply affects the spatial organization of immune microenvironment by depleting immune-signaling and reducing or preventing immune infiltration, supporting the potential implementation of this alteration as ICIs predictive biomarker in DPM.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13046-025-03522-4","type":"journal-article","created":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T04:01:23Z","timestamp":1756353683000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["CDKN2A deletion is associated with immune desertification in diffuse pleural mesothelioma"],"prefix":"10.1186","volume":"44","author":[{"given":"Federica","family":"Torricelli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedetta","family":"Donati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronica","family":"Manicardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mila","family":"Gugnoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Reggiani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gloria","family":"Manzotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierluigi","family":"Di Chiaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristian","family":"Ascione","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simonetta","family":"Piana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riccardo","family":"Valli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Piro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimiliano","family":"Paci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Facciolongo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filippo","family":"Lococo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessia","family":"Ciarrocchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,28]]},"reference":[{"key":"3522_CR1","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1056\/NEJMra1912719","volume":"385","author":"SM Janes","year":"2021","unstructured":"Janes SM, Alrifai D, Fennell DA. Perspectives on the treatment of malignant pleural mesothelioma. N Engl J Med. 2021;385:1207\u201318.","journal-title":"N Engl J Med"},{"key":"3522_CR2","first-page":"491","volume":"1","author":"BM Robinson","year":"2012","unstructured":"Robinson BM. Malignant pleural mesothelioma: an epidemiological perspective. Ann Cardiothorac Surg. 2012;1:491\u20136.","journal-title":"Ann Cardiothorac Surg"},{"key":"3522_CR3","doi-asserted-by":"publisher","first-page":"2262","DOI":"10.1158\/2159-8290.CD-23-0017","volume":"14","author":"B Giotti","year":"2024","unstructured":"Giotti B, Dolasia K, Zhao W, Cai P, Sweeney R, Merritt E, Kiner E, Kim GS, Bhagwat A, Nguyen T, et al. Single-Cell view of tumor microenvironment gradients in pleural mesothelioma. Cancer Discov. 2024;14:2262\u201378.","journal-title":"Cancer Discov"},{"key":"3522_CR4","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1038\/s41588-023-01321-1","volume":"55","author":"L Mangiante","year":"2023","unstructured":"Mangiante L, Alcala N, Sexton-Oates A, Di Genova A, Gonzalez-Perez A, Khandekar A, Bergstrom EN, Kim J, Liu X, Blazquez-Encinas R, et al. Multiomic analysis of malignant pleural mesothelioma identifies molecular axes and specialized tumor profiles driving intertumor heterogeneity. Nat Genet. 2023;55:607\u201318.","journal-title":"Nat Genet"},{"key":"3522_CR5","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1016\/j.jtho.2020.01.025","volume":"15","author":"F Galateau Salle","year":"2020","unstructured":"Galateau Salle F, Le Stang N, Tirode F, Courtiol P, Nicholson AG, Tsao MS, Tazelaar HD, Churg A, Dacic S, Roggli V, et al. Comprehensive molecular and pathologic evaluation of transitional mesothelioma assisted by deep learning approach: A Multi-Institutional study of the international mesothelioma panel from the MESOPATH reference center. J Thorac Oncol. 2020;15:1037\u201353.","journal-title":"J Thorac Oncol"},{"key":"3522_CR6","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1038\/s41467-019-09307-6","volume":"10","author":"Y Blum","year":"2019","unstructured":"Blum Y, Meiller C, Quetel L, Elarouci N, Ayadi M, Tashtanbaeva D, Armenoult L, Montagne F, Tranchant R, Renier A, et al. Dissecting heterogeneity in malignant pleural mesothelioma through histo-molecular gradients for clinical applications. Nat Commun. 2019;10:1333.","journal-title":"Nat Commun"},{"key":"3522_CR7","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1038\/ng.3520","volume":"48","author":"R Bueno","year":"2016","unstructured":"Bueno R, Stawiski EW, Goldstein LD, Durinck S, De Rienzo A, Modrusan Z, Gnad F, Nguyen TT, Jaiswal BS, Chirieac LR, et al. Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations. Nat Genet. 2016;48:407\u201316.","journal-title":"Nat Genet"},{"key":"3522_CR8","doi-asserted-by":"publisher","first-page":"1548","DOI":"10.1158\/2159-8290.CD-18-0804","volume":"8","author":"J Hmeljak","year":"2018","unstructured":"Hmeljak J, Sanchez-Vega F, Hoadley KA, Shih J, Stewart C, Heiman D, Tarpey P, Danilova L, Drill E, Gibb EA, et al. Integrative molecular characterization of malignant pleural mesothelioma. Cancer Discov. 2018;8:1548\u201365.","journal-title":"Cancer Discov"},{"key":"3522_CR9","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1038\/s41571-022-00649-7","volume":"19","author":"DA Fennell","year":"2022","unstructured":"Fennell DA, Dulloo S, Harber J. Immunotherapy approaches for malignant pleural mesothelioma. Nat Rev Clin Oncol. 2022;19:573\u201384.","journal-title":"Nat Rev Clin Oncol"},{"key":"3522_CR10","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1016\/j.annonc.2022.01.074","volume":"33","author":"S Peters","year":"2022","unstructured":"Peters S, Scherpereel A, Cornelissen R, Oulkhouir Y, Greillier L, Kaplan MA, Talbot T, Monnet I, Hiret S, Baas P, et al. First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from checkmate 743. Ann Oncol. 2022;33:488\u201399.","journal-title":"Ann Oncol"},{"key":"3522_CR11","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1016\/j.jtho.2018.05.038","volume":"13","author":"J Quispel-Janssen","year":"2018","unstructured":"Quispel-Janssen J, van der Noort V, de Vries JF, Zimmerman M, Lalezari F, Thunnissen E, Monkhorst K, Schouten R, Schunselaar L, Disselhorst M, et al. Programmed death 1 Blockade with nivolumab in patients with recurrent malignant pleural mesothelioma. J Thorac Oncol. 2018;13:1569\u201376.","journal-title":"J Thorac Oncol"},{"key":"3522_CR12","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/S0140-6736(20)32714-8","volume":"397","author":"P Baas","year":"2021","unstructured":"Baas P, Scherpereel A, Nowak AK, Fujimoto N, Peters S, Tsao AS, Mansfield AS, Popat S, Jahan T, Antonia S, et al. First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial. Lancet. 2021;397:375\u201386.","journal-title":"Lancet"},{"key":"3522_CR13","doi-asserted-by":"publisher","first-page":"e221490","DOI":"10.1001\/jamanetworkopen.2022.1490","volume":"5","author":"T Meirson","year":"2022","unstructured":"Meirson T, Pentimalli F, Cerza F, Baglio G, Gray SG, Correale P, Krstic-Demonacos M, Markel G, Giordano A, Bomze D, Mutti L. Comparison of 3 randomized clinical trials of frontline therapies for malignant pleural mesothelioma. JAMA Netw Open. 2022;5:e221490.","journal-title":"JAMA Netw Open"},{"key":"3522_CR14","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1007\/s10147-023-02292-3","volume":"28","author":"A Nakamura","year":"2023","unstructured":"Nakamura A, Hashimoto M, Kondo N, Matsumoto S, Kuroda A, Minami T, Kitajima K, Kuribayashi K, Kijima T, Hasegawa S. Efficacy and safety of nivolumab with ipilimumab for recurrent malignant pleural mesothelioma after primary surgical intervention. Int J Clin Oncol. 2023;28:409\u201315.","journal-title":"Int J Clin Oncol"},{"key":"3522_CR15","doi-asserted-by":"publisher","first-page":"1121557","DOI":"10.3389\/fimmu.2023.1121557","volume":"14","author":"M Perrino","year":"2023","unstructured":"Perrino M, De Vincenzo F, Cordua N, Borea F, Aliprandi M, Santoro A, Zucali PA. Immunotherapy with immune checkpoint inhibitors and predictive biomarkers in malignant mesothelioma: work still in progress. Front Immunol. 2023;14:1121557.","journal-title":"Front Immunol"},{"key":"3522_CR16","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1016\/S1470-2045(20)30445-9","volume":"21","author":"A Marabelle","year":"2020","unstructured":"Marabelle A, Fakih M, Lopez J, Shah M, Shapira-Frommer R, Nakagawa K, Chung HC, Kindler HL, Lopez-Martin JA, Miller WH Jr., et al. Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. Lancet Oncol. 2020;21:1353\u201365.","journal-title":"Lancet Oncol"},{"key":"3522_CR17","doi-asserted-by":"crossref","unstructured":"Lorenzini E, Ciarrocchi A, Torricelli F. Molecular fingerprints of malignant pleural mesothelioma: not just a matter of genetic alterations. J Clin Med 2021, 10.","DOI":"10.3390\/jcm10112470"},{"key":"3522_CR18","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1097\/JTO.0b013e31823f45c1","volume":"7","author":"DJ Pinato","year":"2012","unstructured":"Pinato DJ, Mauri FA, Ramakrishnan R, Wahab L, Lloyd T, Sharma R. Inflammation-based prognostic indices in malignant pleural mesothelioma. J Thorac Oncol. 2012;7:587\u201394.","journal-title":"J Thorac Oncol"},{"key":"3522_CR19","doi-asserted-by":"publisher","first-page":"12611","DOI":"10.1073\/pnas.1006542107","volume":"107","author":"H Yang","year":"2010","unstructured":"Yang H, Rivera Z, Jube S, Nasu M, Bertino P, Goparaju C, Franzoso G, Lotze MT, Krausz T, Pass HI, et al. Programmed necrosis induced by asbestos in human mesothelial cells causes high-mobility group box 1 protein release and resultant inflammation. Proc Natl Acad Sci U S A. 2010;107:12611\u20136.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"3522_CR20","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1186\/s12943-023-01816-9","volume":"22","author":"F Torricelli","year":"2023","unstructured":"Torricelli F, Donati B, Reggiani F, Manicardi V, Piana S, Valli R, Lococo F, Ciarrocchi A. Spatially resolved, high-dimensional transcriptomics sorts out the evolution of biphasic malignant pleural mesothelioma: new paradigms for immunotherapy. Mol Cancer. 2023;22:114.","journal-title":"Mol Cancer"},{"key":"3522_CR21","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1016\/j.jtho.2018.10.001","volume":"14","author":"AS Mansfield","year":"2019","unstructured":"Mansfield AS, Peikert T, Smadbeck JB, Udell JBM, Garcia-Rivera E, Elsbernd L, Erskine CL, Van Keulen VP, Kosari F, Murphy SJ, et al. Neoantigenic potential of complex chromosomal rearrangements in mesothelioma. J Thorac Oncol. 2019;14:276\u201387.","journal-title":"J Thorac Oncol"},{"key":"3522_CR22","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1038\/s41588-023-01367-1","volume":"55","author":"F Martinez-Jimenez","year":"2023","unstructured":"Martinez-Jimenez F, Priestley P, Shale C, Baber J, Rozemuller E, Cuppen E. Genetic immune escape landscape in primary and metastatic cancer. Nat Genet. 2023;55:820\u201331.","journal-title":"Nat Genet"},{"key":"3522_CR23","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1038\/s41586-022-04696-z","volume":"606","author":"D Hoyos","year":"2022","unstructured":"Hoyos D, Zappasodi R, Schulze I, Sethna Z, de Andrade KC, Bajorin DF, Bandlamudi C, Callahan MK, Funt SA, Hadrup SR, et al. Fundamental immune-oncogenicity trade-offs define driver mutation fitness. Nature. 2022;606:172\u20139.","journal-title":"Nature"},{"key":"3522_CR24","doi-asserted-by":"publisher","first-page":"15713","DOI":"10.1038\/s41598-021-95287-x","volume":"11","author":"S Mizuno","year":"2021","unstructured":"Mizuno S, Yamaguchi R, Hasegawa T, Hayashi S, Fujita M, Zhang F, Koh Y, Lee SY, Yoon SS, Shimizu E, et al. Immunogenomic pan-cancer landscape reveals immune escape mechanisms and immunoediting histories. Sci Rep. 2021;11:15713.","journal-title":"Sci Rep"},{"key":"3522_CR25","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1016\/j.jtho.2021.05.015","volume":"16","author":"J Vandenhoeck","year":"2021","unstructured":"Vandenhoeck J, van Meerbeeck JP, Fransen E, Raskin J, Van Camp G, Op de Beeck K, Lamote K. DNA methylation as a diagnostic biomarker for malignant mesothelioma: A systematic review and Meta-Analysis. J Thorac Oncol. 2021;16:1461\u201378.","journal-title":"J Thorac Oncol"},{"key":"3522_CR26","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1126\/science.aad5944","volume":"351","author":"KJ Mavrakis","year":"2016","unstructured":"Mavrakis KJ, McDonald ER 3rd, Schlabach MR, Billy E, Hoffman GR, deWeck A, Ruddy DA, Venkatesan K, Yu J, McAllister G, et al. Disordered methionine metabolism in MTAP\/CDKN2A-deleted cancers leads to dependence on PRMT5. Science. 2016;351:1208\u201313.","journal-title":"Science"},{"key":"3522_CR27","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1016\/j.ccell.2023.05.001","volume":"41","author":"JK Minami","year":"2023","unstructured":"Minami JK, Morrow D, Bayley NA, Fernandez EG, Salinas JJ, Tse C, Zhu H, Su B, Plawat R, Jones A, et al. CDKN2A deletion remodels lipid metabolism to prime glioblastoma for ferroptosis. Cancer Cell. 2023;41:1048\u2013e10601049.","journal-title":"Cancer Cell"},{"key":"3522_CR28","doi-asserted-by":"publisher","first-page":"20059","DOI":"10.1038\/s41598-021-99524-1","volume":"11","author":"SI Gutiontov","year":"2021","unstructured":"Gutiontov SI, Turchan WT, Spurr LF, Rouhani SJ, Chervin CS, Steinhardt G, Lager AM, Wanjari P, Malik R, Connell PP, et al. CDKN2A loss-of-function predicts immunotherapy resistance in non-small cell lung cancer. Sci Rep. 2021;11:20059.","journal-title":"Sci Rep"},{"key":"3522_CR29","doi-asserted-by":"publisher","first-page":"5606","DOI":"10.1038\/s41467-021-25894-9","volume":"12","author":"G Han","year":"2021","unstructured":"Han G, Yang G, Hao D, Lu Y, Thein K, Simpson BS, Chen J, Sun R, Alhalabi O, Wang R, et al. 9p21 loss confers a cold tumor immune microenvironment and primary resistance to immune checkpoint therapy. Nat Commun. 2021;12:5606.","journal-title":"Nat Commun"},{"key":"3522_CR30","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/s40246-024-00615-7","volume":"18","author":"C Deng","year":"2024","unstructured":"Deng C, Li ZX, Xie CJ, Zhang QL, Hu BS, Wang MD, Mei J, Yang C, Zhong Z, Wang KW. Pan-cancer analysis of CDKN2A alterations identifies a subset of gastric cancer with a cold tumor immune microenvironment. Hum Genomics. 2024;18:55.","journal-title":"Hum Genomics"},{"key":"3522_CR31","doi-asserted-by":"publisher","first-page":"6511","DOI":"10.1158\/1078-0432.CCR-19-0475","volume":"25","author":"J Yu","year":"2019","unstructured":"Yu J, Yan J, Guo Q, Chi Z, Tang B, Zheng B, Yu J, Yin T, Cheng Z, Wu X, et al. Genetic aberrations in the CDK4 pathway are associated with innate resistance to PD-1 Blockade in Chinese patients with Non-Cutaneous melanoma. Clin Cancer Res. 2019;25:6511\u201323.","journal-title":"Clin Cancer Res"},{"key":"3522_CR32","doi-asserted-by":"publisher","first-page":"808208","DOI":"10.3389\/fcell.2021.808208","volume":"9","author":"Z Chen","year":"2021","unstructured":"Chen Z, Guo Y, Zhao D, Zou Q, Yu F, Zhang L, Xu L. Comprehensive analysis revealed that CDKN2A is a biomarker for immune infiltrates in multiple cancers. Front Cell Dev Biol. 2021;9:808208.","journal-title":"Front Cell Dev Biol"},{"key":"3522_CR33","doi-asserted-by":"publisher","first-page":"100411","DOI":"10.1016\/j.xcrm.2021.100411","volume":"2","author":"S Liu","year":"2021","unstructured":"Liu S, Knochelmann HM, Lomeli SH, Hong A, Richardson M, Yang Z, Lim RJ, Wang Y, Dumitras C, Krysan K, et al. Response and recurrence correlates in individuals treated with neoadjuvant anti-PD-1 therapy for resectable oral cavity squamous cell carcinoma. Cell Rep Med. 2021;2:100411.","journal-title":"Cell Rep Med"},{"key":"3522_CR34","doi-asserted-by":"crossref","unstructured":"Luo JP, Wang J, Huang JH. CDKN2A is a prognostic biomarker and correlated with immune infiltrates in hepatocellular carcinoma. Biosci Rep 2021, 41.","DOI":"10.1042\/BSR20211103"},{"key":"3522_CR35","doi-asserted-by":"publisher","first-page":"507","DOI":"10.21037\/jtd-23-1017","volume":"16","author":"L Zhao","year":"2024","unstructured":"Zhao L, Zhou X, Li H, Yin T, Jiang Y. Prognosis of immunotherapy for non-small cell lung cancer with CDKN2A loss of function. J Thorac Dis. 2024;16:507\u201315.","journal-title":"J Thorac Dis"},{"key":"3522_CR36","doi-asserted-by":"publisher","first-page":"3969","DOI":"10.1038\/s41467-021-24112-w","volume":"12","author":"R Banchereau","year":"2021","unstructured":"Banchereau R, Leng N, Zill O, Sokol E, Liu G, Pavlick D, Maund S, Liu LF, Kadel E 3rd, Baldwin N, et al. Molecular determinants of response to PD-L1 Blockade across tumor types. Nat Commun. 2021;12:3969.","journal-title":"Nat Commun"},{"key":"3522_CR37","doi-asserted-by":"publisher","first-page":"1276009","DOI":"10.3389\/fonc.2023.1276009","volume":"13","author":"L Xue","year":"2023","unstructured":"Xue L, Tang W, Zhou J, Xue J, Li Q, Ge X, Lin F, Zhao W, Guo Y. Next-generation sequencing identifies CDKN2A alterations as prognostic biomarkers in recurrent or metastatic head and neck squamous cell carcinoma predominantly receiving immune checkpoint inhibitors. Front Oncol. 2023;13:1276009.","journal-title":"Front Oncol"},{"key":"3522_CR38","doi-asserted-by":"publisher","first-page":"1842","DOI":"10.1016\/j.athoracsur.2021.08.054","volume":"114","author":"HJ Jang","year":"2022","unstructured":"Jang HJ, Truong CY, Lo EM, Holmes HM, Ramos D, Ramineni M, Lee JS, Wang DY, Pietropaolo M, Ripley RT, et al. Inhibition of Cyclin dependent kinase 4\/6 overcomes primary resistance to programmed cell death 1 Blockade in malignant mesothelioma. Ann Thorac Surg. 2022;114:1842\u201352.","journal-title":"Ann Thorac Surg"},{"key":"3522_CR39","doi-asserted-by":"publisher","first-page":"2348","DOI":"10.1158\/1078-0432.CCR-18-2364","volume":"25","author":"G Manzotti","year":"2019","unstructured":"Manzotti G, Torricelli F, Benedetta D, Lococo F, Sancisi V, Rossi G, Piana S, Ciarrocchi A. An Epithelial-to-Mesenchymal transcriptional switch triggers evolution of pulmonary sarcomatoid carcinoma (PSC) and identifies dasatinib as new therapeutic option. Clin Cancer Res. 2019;25:2348\u201360.","journal-title":"Clin Cancer Res"},{"key":"3522_CR40","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1158\/1078-0432.CCR-19-2356","volume":"26","author":"S Luminari","year":"2020","unstructured":"Luminari S, Donati B, Casali M, Valli R, Santi R, Puccini B, Kovalchuk S, Ruffini A, Fama A, Berti V, et al. A gene Expression-based model to predict metabolic response after two courses of ABVD in hodgkin lymphoma patients. Clin Cancer Res. 2020;26:373\u201383.","journal-title":"Clin Cancer Res"},{"key":"3522_CR41","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1158\/2326-6066.CIR-23-0076","volume":"12","author":"B Donati","year":"2024","unstructured":"Donati B, Reggiani F, Torricelli F, Santandrea G, Rossi T, Bisagni A, Gasparini E, Neri A, Cortesi L, Ferrari G, et al. Spatial distribution of immune cells drives resistance to neoadjuvant chemotherapy in Triple-Negative breast cancer. Cancer Immunol Res. 2024;12:120\u201334.","journal-title":"Cancer Immunol Res"},{"key":"3522_CR42","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1038\/s41467-022-28020-5","volume":"13","author":"P Danaher","year":"2022","unstructured":"Danaher P, Kim Y, Nelson B, Griswold M, Yang Z, Piazza E, Beechem JM. Advances in mixed cell Deconvolution enable quantification of cell types in Spatial transcriptomic data. Nat Commun. 2022;13:385.","journal-title":"Nat Commun"},{"key":"3522_CR43","doi-asserted-by":"crossref","unstructured":"Sokol CL, Luster AD. The chemokine system in innate immunity. Cold Spring Harb Perspect Biol 2015, 7.","DOI":"10.1101\/cshperspect.a016303"},{"key":"3522_CR44","doi-asserted-by":"crossref","unstructured":"Alay A, Cordero D, Hijazo-Pechero S, Aliagas E, Lopez-Doriga A, Marin R, Palmero R, Llatjos R, Escobar I, Ramos R et al. Integrative transcriptome analysis of malignant pleural mesothelioma reveals a clinically relevant immune-based classification. J Immunother Cancer 2021, 9.","DOI":"10.1136\/jitc-2020-001601"},{"key":"3522_CR45","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1186\/s13059-023-03005-9","volume":"24","author":"Y Shi","year":"2023","unstructured":"Shi Y, Jing B, Xi R. Comprehensive analysis of neoantigens derived from structural variation across whole genomes from 2528 tumors. Genome Biol. 2023;24:169.","journal-title":"Genome Biol"},{"key":"3522_CR46","doi-asserted-by":"publisher","first-page":"19138","DOI":"10.1038\/s41598-021-98414-w","volume":"11","author":"A Nastase","year":"2021","unstructured":"Nastase A, Mandal A, Lu SK, Anbunathan H, Morris-Rosendahl D, Zhang YZ, Sun XM, Gennatas S, Rintoul RC, Edwards M, et al. Integrated genomics point to immune vulnerabilities in pleural mesothelioma. Sci Rep. 2021;11:19138.","journal-title":"Sci Rep"},{"key":"3522_CR47","doi-asserted-by":"publisher","first-page":"1746","DOI":"10.1002\/1878-0261.13206","volume":"16","author":"Y Peng","year":"2022","unstructured":"Peng Y, Chen Y, Song M, Zhang X, Li P, Yu X, Huang Y, Zhang N, Ji L, Xia L, et al. Co-occurrence of CDKN2A\/B and IFN-I homozygous deletions correlates with an immunosuppressive phenotype and poor prognosis in lung adenocarcinoma. Mol Oncol. 2022;16:1746\u201360.","journal-title":"Mol Oncol"},{"key":"3522_CR48","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1038\/s43018-022-00443-5","volume":"3","author":"FM Barriga","year":"2022","unstructured":"Barriga FM, Tsanov KM, Ho YJ, Sohail N, Zhang A, Baslan T, Wuest AN, Del Priore I, Meskauskaite B, Livshits G, et al. MACHETE identifies interferon-encompassing chromosome 9p21.3 deletions as mediators of immune evasion and metastasis. Nat Cancer. 2022;3:1367\u201385.","journal-title":"Nat Cancer"},{"key":"3522_CR49","doi-asserted-by":"publisher","first-page":"4183","DOI":"10.1038\/s41598-022-07697-0","volume":"12","author":"LJ Hansen","year":"2022","unstructured":"Hansen LJ, Yang R, Roso K, Wang W, Chen L, Yang Q, Pirozzi CJ, He Y. MTAP loss correlates with an immunosuppressive profile in GBM and its substrate MTA stimulates alternative macrophage polarization. Sci Rep. 2022;12:4183.","journal-title":"Sci Rep"},{"key":"3522_CR50","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.lungcan.2022.08.019","volume":"173","author":"MJ Disselhorst","year":"2022","unstructured":"Disselhorst MJ, Lubeck Y, van der Noort V, Quispel-Janssen J, Seignette IM, Sanders J, Peters D, Hooijberg E, Baas P. Immune cells in mesothelioma microenvironment simplistic marker of response to nivolumab plus ipilimumab? Lung Cancer. 2022;173:49\u201352.","journal-title":"Lung Cancer"},{"key":"3522_CR51","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1016\/S2213-2600(21)00043-6","volume":"9","author":"L Calabro","year":"2021","unstructured":"Calabro L, Rossi G, Morra A, Rosati C, Cutaia O, Daffina MG, Altomonte M, Di Giacomo AM, Casula M, Fazio C, et al. Tremelimumab plus durvalumab retreatment and 4-year outcomes in patients with mesothelioma: a follow-up of the open label, non-randomised, phase 2 NIBIT-MESO-1 study. Lancet Respir Med. 2021;9:969\u201376.","journal-title":"Lancet Respir Med"},{"key":"3522_CR52","doi-asserted-by":"publisher","first-page":"7187","DOI":"10.1038\/s41467-024-49842-5","volume":"15","author":"M Zhang","year":"2024","unstructured":"Zhang M, Bzura A, Baitei EY, Zhou Z, Spicer JB, Poile C, Rogel J, Branson A, King A, Barber S, et al. A gut microbiota rheostat forecasts responsiveness to PD-L1 and VEGF Blockade in mesothelioma. Nat Commun. 2024;15:7187.","journal-title":"Nat Commun"},{"key":"3522_CR53","doi-asserted-by":"publisher","first-page":"4025","DOI":"10.1158\/1078-0432.CCR-21-0575","volume":"27","author":"E Adib","year":"2021","unstructured":"Adib E, Nassar AH, Akl EW, Abou Alaiwi S, Nuzzo PV, Mouhieddine TH, Sonpavde G, Haddad RI, Mouw KW, Giannakis M, et al. CDKN2A alterations and response to immunotherapy in solid tumors. Clin Cancer Res. 2021;27:4025\u201335.","journal-title":"Clin Cancer Res"}],"container-title":["Journal of Experimental &amp; Clinical Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-025-03522-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13046-025-03522-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-025-03522-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T20:46:08Z","timestamp":1757450768000},"score":1,"resource":{"primary":{"URL":"https:\/\/jeccr.biomedcentral.com\/articles\/10.1186\/s13046-025-03522-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,28]]},"references-count":53,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3522"],"URL":"https:\/\/doi.org\/10.1186\/s13046-025-03522-4","relation":{},"ISSN":["1756-9966"],"issn-type":[{"value":"1756-9966","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,28]]},"assertion":[{"value":"25 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the AVEN ethical committee (131\/2023\/TESS\/IRCCSRE \u2013 DIMPLE).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not Applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"256"}}